Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy

British Journal of Haematology
Richa ManwaniAshutosh D Wechalekar

Abstract

Bortezomib is standard treatment in AL amyloidosis (AL), but is contraindicated in patients with significant neuropathy. Carfilzomib, a second-generation proteosomal inhibitor, results in a lower incidence of neuropathy than bortezomib, but data in AL is scant. We report a cohort of five AL patients treated with upfront carfilzomib. All had cardiac, peripheral and autonomic neuropathy at presentation. All achieved at least a very good partial haematological response. There was no worsening in cardiac function, peripheral or autonomic neuropathy. Carfilzomib is an effective upfront treatment option in AL patients with peripheral and/or autonomic neuropathy (without severe cardiac or renal involvement).

References

Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela DispenzieriAllan S Jaffe
Mar 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shirin Arastu-KapurChristopher J Kirk

❮ Previous
Next ❯

Citations

Mar 12, 2020·Leukemia & Lymphoma·Shweta DeshpandeEli Muchtar
May 8, 2020·Journal of the Peripheral Nervous System : JPNS·Laura Obici, David Adams
Aug 1, 2020·Expert Opinion on Emerging Drugs·Rajshekhar Chakraborty, Suzanne Lentzsch
Feb 6, 2020·British Journal of Haematology·Giovanni PalladiniGiampaolo Merlini
Jul 30, 2020·Expert Review of Hematology·Marco BassetGiampaolo Merlini
May 13, 2020·Current Hematologic Malignancy Reports·Joselle CookRahma Warsame
Sep 5, 2020·HemaSphere·Despina FotiouEfstathios Kastritis
Oct 9, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·David M HughesVaishali Sanchorawala
Feb 16, 2021·Expert Opinion on Drug Safety·Mario NuvoloneGiovanni Palladini
May 14, 2021·Circulation Research·Jan M GriffinMathew S Maurer
May 20, 2021·Blood Cancer Journal·Rama Al HamedMohamad Mohty
Jun 6, 2021·ESC Heart Failure·Robert Daniel AdamRuxandra Jurcuţ
May 17, 2021·Blood Cancer Journal·M Hasib Sidiqi, Morie A Gertz
Jun 12, 2020·Acta Haematologica·Layla Van Doren, Suzanne Lentzsch
May 1, 2020·Acta Haematologica·Paolo Milani, Giovanni Palladini
Nov 17, 2021·Heart Failure Reviews·Pranav ChandrashekarBarry H Trachtenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.

Related Papers

Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis
Marco BassetGiampaolo Merlini
© 2021 Meta ULC. All rights reserved